CALC

CalciMedica is a pre-revenue, clinical-stage biopharma whose entire value rests on a single CRAC-channel platform (Auxora/zegocractin) that has not cleared a pivotal trial. The FY2025 numbers describe a company running on fumes: $11.5M cash against $21.2M of annual operating cash burn implies roughly six months of runway, and stockholders' equity is already negative (-$6.64M) with liabilities up 275.8% YoY to $20.2M. A liabilities/equity of -3.05x and a -$189M accumulated deficit confirm this is a serial cash-consumer, not a business — five straight years of losses ($35.8M, $7.82M, $34.4M, $13.7M, $29.6M) with no revenue line at all.

The filing narrative makes the setup worse, not better. In January 2026 the Independent Data Monitoring Committee forced discontinuation of the KOURAGE Phase 2 trial in AKI/AHRF over a mortality imbalance — the single most damaging event a critical-care drug can face, regardless of the company's (self-interested) claim that it wasn't drug-related toxicity. The pivot is now to acute pancreatitis, where management only 'expects to finalize the pivotal program design in the first half of 2026,' and to a preclinical PAH asset (CM5480) whose IND isn't even anticipated until 2027. That is years of expensive development ahead with essentially no cash to fund it, and management explicitly conditions further research on 'depending on financing.'